InnovaRx Innova Health Strategies

N39.3

Stress incontinence (female) (male)

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 16 never code together
N39code
Excludes2
  • hematuria NOS (R31.-)R31.-
  • recurrent or persistent hematuria (N02.-)N02.-
  • recurrent or persistent hematuria with specified morphological lesion (N02.-)N02.-
  • proteinuria NOS (R80.-)R80.-
N39.3code
Excludes1
N30-N39block
Excludes2
  • urinary infection (complicating):
  • abortion or ectopic or molar pregnancy (O00-O07, O08.8)O00-O07O08.8
  • pregnancy, childbirth and the puerperium (O23.-, O75.3, O86.2-)O23.-O75.3O86.2-
N00-N99chapter
Excludes2
  • certain conditions originating in the perinatal period (P04-P96)P04-P96
  • certain infectious and parasitic diseases (A00-B99)A00-B99
  • complications of pregnancy, childbirth and the puerperium (O00-O9A)O00-O9A
  • congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
  • endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
  • injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
  • neoplasms (C00-D49)C00-D49
  • symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)R00-R94

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 1
N39.3code
Code also
Index entries leading here 1
  • Incontinence R32
    • stress (female) (male) N39.3
    • urine (urinary) R32
      • stress (female) (male) N39.3
Alongside this code 4 same parent — N39
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
N39
Block
N30-N39
Siblings
4

Present FY2024–FY2027.